Methods also are provided for detecting the presence of the Met (Ex14del) mutant protein.Tian YuanCecchi FabiolaHembrough Todd
[3].Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population[J]....
[3].Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, singl...
[4] Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small cell lung cancer are associated with advanced age and stage-dependend MET genomic amplification and c-MET overexpression. J Clin Oncol 2016;34:721-30. [5] Zheng D, Wang R, Ye T, et al. MET exon 14...
A key negative regulatory event is phosphorylation of the juxtamembrane tyrosine Y1003 encoded by MET exon 14. This leads to the recruitment of the E3 ubiquitin-protein ligase casitas B-lineage lymphoma (CBL), resulting in ubiquitination, internalisation, and proteosomal degradation of MET [[45],...
9036 Background: Exon 14 skipping mutations in the mesenchymal-epithelial transition ( MET) gene are reported in 2-5% of lung adenocarcinomas and are mutually exclusive of other driver mutations. Small-molecule MET tyrosine kinase inhibitors, capmatinib and tepotinib, showed durable responses in prev...
Somatic mutations lead to an oncogenic deletion of MET in lung cancer Cancer Res, 66 (1) (2006), pp. 283-289 View in ScopusGoogle Scholar 10. G.M. Frampton, S.M. Ali, M. Rosenzweig, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types an...
3D). There was no evidence for monosomy 14 or 1p/19q co-deletion. OncoKids showed no established clinically significant sequence variants, gene fusions, or amplification events. Subsequent RNAseq analysis revealed the same CLIP2::MET fusion as seen in Case 1, with exon 11 of CLIP2 fused ...
该病例为MET 14号外显子跳跃突变的老年晚期肺鳞癌患者,经赛沃替尼治疗至今已经10个月,病灶持续缩小,并在最近一次随访时肿瘤缩小达42%,实现PR,而且治疗过程中患者的总体耐受性良好。 该病例再次印证了赛沃替尼在肺鳞癌患者中的良好疗效与安全性...
KwonD, KohJ, KimS, et al.MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics[J]. Lung Cancer, 2017, 106: 131-...